Article

AMO iFS laser receives FDA clearance for arcuate incisions

Abbott Medical Optics announced FDA clearance to use its iFS advanced femtosecond laser to create bow-shaped or curved arcuate incisions in corneal surgery, including cataract surgery.

Chicago-Abbott Medical Optics (AMO) announced FDA clearance to use its iFS advanced femtosecond laser to create bow-shaped or curved arcuate incisions in corneal surgery, including cataract surgery.

The iFS laser is currently used to create LASIK flaps and other corneal incisions in the eye and is the fifth generation of IntraLase technology, which has been used in more than 5 million procedures worldwide.

With this new clearance, the iFS laser now gives surgeons the ability to make precise, bladeless arcuate incisions during surgery and customize the incision for each individual patient.

“This is a major advancement and expansion of our femtosecond laser technology," said Jim Mazzo, senior vice president, AMO. "Abbott has been a pioneer in the ophthalmic use of femtosecond lasers, and this new use of our technology demonstrates our leadership position in this very dynamic and competitive market. This is an important step as we look to utilize femtosecond laser technology as a potential standard of care during the cataract procedure.”

Study data support that the iFS femtosecond laser creates arcuate incisions safely and effectively as prescribed by the physician, and complies with applicable safety standards. This new use of the iFS femtosecond laser is available now in the United States.

For more articles in this issue of Ophthalmology Times Conference Briefclick here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.